The human Cks (also designated as CksHs) family consists of 2 well-conserved members, Cks1 and Cks2, both of which are identified based on the sequence homology to yeast suc1 and Cks1 (Cdc28 kinase subunit 1) that are essential for cell cycle-control.1–3 Emerging evidence shows that the 2 Cks members in mammalian cells have distinct regulatory function from the yeast counterparts. Cks1 is required for SCFSkp2-mediated ubiquitination and degradation of p27kip1, which is essential for the G1/S transition during the cell cycle.4, 5 Although function of Cks2 in the cell-cycle is not clear, expression of both Cks1 and Cks2 has been shown oscillates during the cell cycle and is positively related to cell proliferation.6 Recently, Cks2 has been shown essential for the first metaphase/anaphase transition of mammalian meiosis.7
Numerous reports demonstrate that expression of Cks2 is frequently elevated in tumors of different tissue origins, including nasopharyngeal carcinoma, melanocytic tumors, Wilms tumor, breast, bladder, cervical, esophageal, lymphoid and metastatic colon cancer.6, 8–14 In addition, expression of Cks2 is downregulated by p53, a tumor suppressor, at the transcription and the protein levels.15 Similarly, elevated expression of Cks1 has been found in tumors from a variety of tissue origins, and is correlated with poor survival rate of oral squamous cell carcinoma.16–23 Knockdown of Cks1 inhibits growth and tumorigenicity of oral squamous cells.23 Consistent with the finding that Cks1 is a negative regulator of a cell cycle control protein, p27kip1, elevated expression of Cks1 is found coincident with the reduction of p27kip1 proteins in tumor cells. Expression of p27kip1 is often aberrantly reduced in cancer cells, including prostate cancer cells. We recently reported that the fibroblast growth factor (FGF) signaling axis directly regulates activity of Cks1 during the G1/S transition in the cell cycle through FGF receptor substrate 2α (FRS2α), a proximal FGF receptor-interactive adaptor protein of the FGF receptor tyrosine kinase, which connects multiple downstream signaling molecules to the FGF receptor tyrosine kinase.24
The prostate is an accessory organ of the male reproductive system, which consists of epithelial and stromal compartments separated by basement membranes. Cancers arising from the prostate epithelium are the most commonly diagnosed cancer and the second most common cause of cancer death in American males. In America alone, about 230,000 new cases and 30,000 deaths are expected every year. To date, whether the Cks family is overexpressed in prostate tumor, and if yes, whether aberrantly expressed Cks contributes to prostate tumor initiation and progression remain to be characterized. Recently, it has been shown that Cks1 expression is associated with the aggressive behavior of prostate cancer.25 In addition, treating LNCaP prostate cancer cells with an herbal mixture, PC-SPES, inhibits cell proliferation and reduces expression of Cks2.26
To determine whether overexpression of the Cks family was associated with prostate tumorigenesis, we analyzed the expression pattern of Cks1 and Cks2 in the Dunning prostate tumor model of rats, the TRAMP prostate cancer model of mice, human prostate cancer cell lines, and human prostate cancer samples. The results showed that in comparison with normal prostate tissues that only weakly express Cks1 and Cks2, all tested human, rat and mouse prostate tumor tissues and cells exhibited elevated expression of Cks1 and Cks2. Forced expression of Cks1 and Cks2 by transfection in benign prostate tumor cells somewhat promoted cell population increases. Consistently, knockdown of Cks1 and Cks2 expression by shRNA in malignant AT3 cells inhibited cell population growth. In addition, knockdown of Cks1 expression also inhibited anchorage-independent growth, and migration activities, and knockdown of Cks2 expression induced the cells to undergo massive program cell death, especially when the cells were maintained in suboptimal growth condition. The results suggested that elevated expressed Cks1 may contribute to prostate tumorigenesis by promoting proliferation, anchorage-independent growth and migration of the cells, and Cks2 by protecting cells from undergoing programmed cell death. The finding also provides new hints for cancer therapeutic strategies based on inhibition of the Cks activity.
Material and methods
All animals were housed in the Program of Animal Resources at the Institute of Biosciences and Technology and were handled in accordance with the principles and procedures of the Guide for the Care and Use of Laboratory Animals. All experimental procedures were approved by the Institutional Animal Care and Use Committee. Genotypes of the mice were determined by PCR analyses as described.27, 28 For tumorigenesis, 1 × 106 cells were implanted subcutaneously in 0.1 ml MEM medium. The mice were observed carefully, and the palpable tumors were recorded daily. Tumors were harvested and histologically characterized as described.27, 28 Tissues were fixed with 4% paraformaldehyde paraffin embedded. In situ hybridization was carried out with paraffin-embedded sections as described.29
Full-length cDNAs for mouse Cks1 and Cks2 were RT-PCR amplified from mouse embryo RNA pools with primers mcks1-u: CTCCTGCAGAGCGATCATGTCGCACAAACA and mcks1-d: CTTCTGCAGCTTCATTTCTTTGGTTTCTTG, and mcks2-u: TTTCTGCAGCGCGCCGGCAGGATGGCC and mcks2-d: AGA TAAGCTTCATTTTTGTTGTTCTTTTGG, respectively. The cDNAs were cloned into the pBluescript SK vector for sequence verification and pEGFP-N3 vector for expression in mammalian cells.24
The cDNA for rat Cks1-shRNA was constructed by annealing the primers pRcks1-t: GATCCGTCAGAAGCATGTGAAATC TTCAAGAGAGATTTCACATGCTTCTGACTTTTTTACGCG TG and pRcks1-b: AATTCACGCGTAAAAAAGTCAGAAG CATGTGAAATCTCTCTTGAAGATTTCACATGCTTCTGAC G; rat Cks2-shRNA by pRcks2-t: GATCC GCCAGAACCGCA TATTCTTTTC AAGAGAAAGAATATGCGGTTCTGGCTTTT TTACGCGTG and pRcks2-b: AATTCAC GCGTAAAAAAGC CAGAACCGCATATTCTTTCTCTTGAAAAGAATATGCGGT TCTGGCG; mouse Cks1 shRNA by pMcks1-t: GATCCGGTC CACTATATGATCCATTTCA AGAGAATGGATCATATAGTG GACCTTTTTTACGCGTG and pMcks1-b: AATTCACGCGT AAAAAAGGTCCACTATATGATCCATTCTCTTGAAATGGA TCATATAGTGGACCG and mouse Cks2 shRNA by pMcks2-t: GATCCGTCCAACAGAGTCTAGGATTTCAAGAGAATCCTA GACTCTGTTGGACTTTTTTACGCGTG, and pMcks2-b: AAT TCACGCGTAAAAAAGTCCAACAGAGTCTAGGATTCTCTT GAAATCCTAGACTCTGTTGGACG. The annealed oligonucleotides were cloned to the pSIREN-RetroQ-Tet vectors (Clontech, Mountain View, CA) and the sequences were verified.
Gene expression analyses
Expression of Cks1 and Cks2 was analyzed by RT-PCR and RNase protection assay (RPA). Total RNA was extracted from tissues or cells with RNAzol (Ambion, San Antonio, TX). Reverse transcriptions were carried out with 1 μg RNA and 2.5 μg random hexamers with SuperScript reverse transcription kit (Invitrogen, Carlsbad, CA). PCR was carried out for Cks1 and Cks2 with the indicated primers for 30 cycles at 94, 55 and 72°C for 1 min each using the Taq DNA Polymerase (Promega, Madison, WI). Primers for rat Cks1 are rcks1-u: CTGGATCCGCAAATTCACAC CATCCCTG and rcks1-d: GTGATATCCTGATAGCGTGACCG TGTTG, and rat Cks2 are rcks2-u: CGTTTCCTT GTCCCGGTTT and rcks2-d: TATGCGGTTCTGGCTCATGG, respectively. Primers for human Cks1 are hcks1-u: CTCCTGCAGAGCGAT CATGTCGCACAAACA and hcks1-d: CTTCTGCAGCTTCA TTTCTTTGGTTTCTTG. Primers for human Cks2 are hcks2-u: TTTCTGCAGCGCGCCGGCAGGATGGCC and hcks2-d: AGA TAAGCTTCATTTTTGTTGTTCTTTTGG. The RT-PCR products were verified in sizes on a 2% agarose gel. For RPA, the RNA probe was transcribed and radiolabeled with α-[32P]UTP from the Cks1 and Cks2 cDNA templates with the Maxiscript Kit (Ambion, San Antonio, TX).30 The labeled antisense RNA probe was hybridized with 25 μg of total RNA at 68°C for 11 min followed by incubation with RNase A1/T1 at 37°C for 30 min. Protected fragments were separated on 5% polyacrylamide sequencing gels and the protected fragments were visualized by autoradiography.
The cells were maintained in RD media (50% RPMI, 50% DMEM) containing 5% fetal bovine serum (FBS). For proliferation assays, 103 cells per well were inoculated to 24-well plates containing 1 ml of RD medium with 5%, or indicated concentrations of FBS. The cell numbers were counted daily. For soft agar growth assays, 1,000 cells per well were mixed with 0.6% top agar at a ratio of 1:1 and inoculated to 6-well plates containing 1% base agar. The final serum concentration in the top and base agar was 5%. The cells were cultured for 3–4 weeks until the colonies were visible. The colonies were stained with Crystal Purple for observation and quantification. Data are mean and standard deviation of 3 separate samples.
To establish stable cell lines expressing the tetracycline-controlled transcriptional suppressor (tTS), cells (5 × 105) were transfected with the ptTS-Neo Vector (Clontech, Mountain View, CA) and selected for G418 resistant. The healthy colonies with the highest tetracycline inducible expression of the pSIREN-RetroQ-Tet-Luc reporter were picked for further transfection with pSIREN-RetroQ-Tet-Cks1/Cks2-shRNA plasmids. After being selectively cultured in hygromycin (200 μg/ml) media, the colonies were screening for the best knockdown efficiency induced by doxycycline at a concentration of 1 μg/ml. RT-PCR analyses were employed for assessing the knockdown efficiency. For overexpression analyses, the stable transfectants were pooled to avoid clonal deviations. RT-PCR analyses were used to confirm expression of Cks1 and Cks2.
Cell migration assay
Prior to the experiments, the cells were cultured in the presence doxycycline for over 48 hr to induce expression of shRNAs where indicated. The cells (2.5 × 104) in 0.5 ml of serum-free RD medium were inoculated to gelatin-coated 6.5 mm Millicell inserts of 8 μm pore size (COSTA Corning NY) placed in 12-well culture plates, which contain 10% FBS RD medium with or without doxycycline. After incubation at 37°C for 12 hr, the cells migrated to the outer surface of the membrane were fixed, stained with hematoxylin and counted under a microscope.
Cells (3 × 105) cultured in 6-well dishes in 5% FBS/RD medium were treated with doxycycline for the indicated days to induce shRNA expression. The cells were then stained with the APOPercentage™ dye (Biocolor, Newtonabbey, Northern Ireland) for 30 min. The stained cells were visualized by microscopy, and the positive cells were quantified. For Annexin V staining, the cells (1–5 × 105) were harvested 48 hr after the transfection and suspended in 500 μl binding buffer containing 1% Annexin V-Cy3. The cells were replated on 6-well dishes and the Annexin V-Cy3 stained cells were observed under a fluorescent microscope.
The cells (2 × 105) in 6-well plates were cultured in 5% FBS for 24 hr and the expression of shRNA was induced for 48 hr. The cells were then lysed with 0.5% Triton-PBS. Aliquots containing 10 μg of protein were subjected to SDS-polyacrylamide gel electrophoreses (SDS-PAGE) on 3 gels, and were electroblotted to nylon membranes for Western blot analyses with the indicated antibodies. For Akt and Bcl-xl staining, the membrane was cut into 2 pieces for staining with anti-Akt and anti-Bcl-xl antibodies individually. The other 2 membranes were stained with anti-Bad and anti-β-actin, respectively. The experiments were repeated for 3 times and the representative results were showed. The specifically bound antibodies were detected with the ECL-plus chemiluminescent detection reagents. Anti-p27kip1, anti-Bcl-xl, anti-Bad and anti-β-actin antibodies was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Expression of Cks1 and Cks2 is elevated in prostate cancer
To determine whether expression of Cks1 and Cks2 was elevated in prostate tumors, we employed the RPA to quantitatively analyze expression of Cks1 and Cks2 mRNA in rat prostates and the Dunning3327 (DT3) rat prostate tumors, which consist of androgen-dependent benign DT tumors and androgen-independent malignant AT tumors.31, 32 The results showed that Cks1 was weakly expressed in normal rat prostates and the benign DT3 tumors; the expression was apparently stronger in the malignant AT tumors than in normal prostates and benign prostate tumors (Fig. 1aa′). The Cks2 expression in normal rat prostates was below the detection limit (Fig. 1aa′). Strong Cks2 expression was evident in benign DT3 and malignant AT tumors, as well as in cell lines derived from both tumors, including the DTE epithelial and DTS stromal cells derived from benign DT tumors, and AT3 cells from the malignant AT tumors (Fig. 1aa′). To determine whether Cks1 and Cks2 were overexpressed in other prostate tumors, RT-PCR (30 cycles) was employed to assess Cks1 and Cks2 expression in the TRAMP autochthonous mouse prostate tumor model.28 Expression of Cks1 and Cks2 was apparent in TRAMP tumor tissues and the C2 cells derived from TRAMP tumors. Under the same condition, Cks expression was undetectable in adult mouse prostates (Fig. 1ab′).
To investigate whether aberrant expression of Cks1 and Cks2 was associated with human prostate cancers, RT-PCR analyses were employed to assess the expression of Cks1 and Cks2 in human prostate cell lines, including nontumorigenic prostate epithelial cell line PNTIA, low tumorigenic LNCaP and highly tumorigenic DU-145 and PC3 cells (Fig 1ac′). The results showed that expression of Cks1 and Cks2 mRNA was evident in all tested cell lines, including the T antigen-immortalized human prostate epithelial cells isolated from the normal prostate tissues adjacent to prostate tumors.
Furthermore, real-time RT-PCR analyses of cDNAs prepared from human prostate cancer and its peripheral normal tissues showed that a significant number of the tested tumors expressed Cks2 at a higher level than did the controls. Overall, relative to normal peripheral tissues, elevated expression of Cks2 was apparent in the tumor tissues (p < 0.01), whereas the difference in Cks1 expression was not statistically significant between the tumor and normal peripheral zone tissues (Fig. 1b and data not shown). In situ hybridization also demonstrated that expression of Cks2 was evident in lesion foci with high-grade prostate intraepithelial neoplasia (PIN) in human prostate (Fig. 1ca′), whereas no Cks2 expression was detectable in the epithelium with normal tissue histology (Fig. 1cb′). To further investigate whether aberrant expression of Cks was associated with prostate tumorigenesis, prostate tissues were harvested from TRAMP mice and wildtype littermates at the age of 4–8 weeks. Tissue sections with relatively normal tissue structures, low to medium grade PIN, high grade PIN, and adenocarcinomas were selected for in situ hybridization analyses (Fig. 1d). The results confirmed that Cks1 and Cks2 expression in normal prostate was under the detection limit (panels a,b). The expression of Cks was also very low in foci with low grade PIN lesions (data not shown), whereas the expression was apparent in tissues with lesions of high grade PIN (panels c and d, arrows), and adenocarcinomas (panels e and f, arrows).
Knockdown of Cks1 and Cks2 expression inhibits population growth of prostate cancer cells
To study the role of aberrantly expressed Cks1 and Cks2 in prostatic cancer cells, expression of Cks1 and Cks2 were knocked down in malignant AT3 cells by stably transfected with cDNAs encoding Cks1- or Cks2-shRNA cloned in a doxycycline-inducible vector. Real-time RT-PCR analyses revealed that expression of Cks1 and Cks2 in the cells was reduced to about 25 and 35% of the original levels in the presence of doxycycline inducers. To determine whether knockdown of Cks1 or Cks2 expression inhibited cell growth, population curves of the cells cultured in normal media containing 5% FBS were measured with and without the induction of Cks1- and Cks2-shRNA expression. The results showed that Cks1 knockdown (Fig. 2a) reduced the population growth rate of the cells. Under the same condition, doxycycline treatment did not affect the growth rate of cells expressing stochastic shRNA and Cks2 shRNA (Fig. 2a and data not shown). Yet, when the cells were cultured in suboptimal media, including low serum concentration (data not shown) or containing 50% medium conditioned by AT3 cells (Fig. 2a), the population doubling rate was apparently reduced by expression of Cks2-shRNA. Western analyses demonstrated that the protein abundance of p27kip1 was elevated in Cks1, but not Cks2, knockdown cells (Fig. 2b), which was consistent with the finding that Cks1 triggers degradation of p27kip1. The results suggest Cks2 may be critical for cells to grow or survive in nonoptimal conditions. Comparable to the cells expressing GFP alone or untransfected cells, DTE cells expressing either Cks1- or Cks2-GFP fusion proteins exhibited an accelerated population growth activity (Fig. 2c). Interestingly, only the cells overexpressing Cks1, but not Cks2, had reduced p27kip1 abundance, which is a negative regulator of cell cycle progression (Fig. 2d). The results suggest that overexpressed Cks1 accelerates the population growth by directly promoting p27kip1 degradation and Cks2 by other mechanisms.
Knockdown of expression of Cks2 induces programmed cell death
To further investigate the role of elevated expressed Cks1 or Cks2 in prostate tumor cells, the colony formation activity of AT3 cells stably transfected with the inducible shRNA constructs were assessed. It was apparent that the colony numbers were reduced by knockdown of Cks1 (Fig. 3a), suggesting that elevated expression of Cks1 in malignant AT3 cells contributed to the anchorage-independent growth activity. In contrast, knockdown of Cks2 expression only slightly reduced the colony number, suggestive that Cks2 might not be essential for the anchorage-independent growth activity. Furthermore, cell migration assay showed that knocking down Cks1, but not Cks2, expression in AT3 cells significantly reduced cell migration activity (Fig. 3b). Separated experiments revealed that force expression of Cks1 and Cks2 to benign DTE cells did not affect the anchorage-independent growth and cell migration activities (data not shown).
Although knockdown of Cks2 expression did not severely inhibit migration and anchorage-independent growth in AT3 cells, it induced dramatic cell morphology change within 12 hr after the induction especially when the cells were cultured in a suboptimal culture medium that contained 50% of fresh medium and 50% of conditioned media. Most cells became rounded and loosely attached to the culture surface (Figs. 3c and 3d), suggestive of programmed cell death. To test this possibility, the cells cultured in suboptimal conditions were stained with the APOPercentage™ dye 12–72 hr after the induction with doxycycline, which stained the apoptotic cells that lost the membrane potential. The results showed that knockdown of Cks2 expression induced significant cell death within 12 hr (Fig. 4a). In contrast, knockdown of Cks1 expression did not induce apoptosis under the same condition. Consistently, knockdown of Cks2 expression increased the caspase 3 activity by at least 2-folds (Fig. 4b). To further confirm this, Western blot analyses were carried out to assess the abundance of apoptosis markers at the protein levels. It was apparent that knockdown of Cks2 expression increased Bad and somewhat decreased Bcl-xl and Akt expression at the protein levels (Fig. 4c).
To determine whether knockdown of Cks2 expression also induced apoptosis in other prostate cancer cells, Cks2 shRNA was transiently expressed in mouse prostate tumor cells (C2) derived from TRAMP tumors.28 To monitor the transfected cells, the GFP was coexpressed in the cells. Since about 85% of the transfectants are cotransfected with more than 1 vector, the majority of the GFP expressing cells would also express Cks2 shRNA. If knocking down Cks2 expression induced apoptosis in C2 cells, the majority of GFP positive cells would undergo apoptosis. The cells were stained with Cy3 conjugated Annexin V that recognized phosphatidylserine exposed only in apoptotic cell surface. Fluorescent microscopy analyses showed that, indeed, at 48 hr after the transfection, about 80% of GFP-positive cells were stained with Annexin V-Cy3, suggestive of the programmed cell death (Fig. 5). It is noticeable that not every GFP positive cells underwent apoptosis, and not every apoptotic cells expressed GFP, which reflects the fact that not every GFP positive cells also expressed Cks2 shRNA, and vice versa. In contrast, coexpression of stochastic shRNA and GFP or GFP alone rarely induced apoptosis in cells (Fig. 5). Similarly, knockdown of Cks2 expression also induced apoptosis in human DU145 cells (data not shown). Thus, the results further suggest a role of aberrantly expressed Cks2 in protecting prostate cancer cells from undergoing apoptosis.
Knockdown of Cks2 expression inhibits tumorigenicity of prostate cancer cells
The data that elevated Cks2 expression protected the cells from undergoing programmed cell death prompted us to investigate whether knockdown of Cks2 expression inhibited tumorigenicity of the cells. TRAMP C2 cells stably transfected with the inducible Cks2-shRNA construct were implanted to synergetic C57 mice as described.33 Doxycycline was administrated through drinking water to induce expression of Cks2-shRNA. As expected, the control cells gave rise to tumors within 2–3 weeks and caused the death of host animals by the time of 30–45 days. In sharp contrast, only 14% animals implanted with the cells expressing Cks2-shRNA died by the time of 55 days (Fig. 6a). The results were confirmed by separated experiments with another individual clone. It is noticeable that the Cks2-shRNA transfectants were less tumorigenic than the control even in the absence of doxycycline inducers. RT-PCR analyses revealed that expression of Cks2 in the 2 individual transfectants was somewhat lower than the cells expressing stochastic shRNA even in the absence of doxycycline (Fig. 6b), suggestive of leaky expression of Cks2 shRNA. Thus, the reduction in Cks2 expression may inhibit tumorigenesis of the cells in the absence of doxycycline inducer.
Here we demonstrate that expression of Cks1 and Cks2 was elevated in prostate tumors, including the Dunning prostate tumors in rat, the TRAMP tumors in mouse, and more importantly, in human prostate tumors and cell lines. Forced expression of Cks1 and Cks2 in benign prostate tumor epithelial cells accelerated cell growth; knockdown of Cks1 and Cks2 malignant prostate tumor cells inhibited cell growth, anchorage-independent growth and migration activity. In addition, knockdown of Cks2 expression induced apoptosis in vitro and compromised tumorigenic activity of the cells in vivo. The results suggest that elevated expression of Cks1 may contribute to tumorigenicity of prostate tumor cells by promoting cell growth and elevated expression of Cks2 by protecting the cells from undergoing apoptosis.
The function of the Cks family appears to be complicated. In yeast, both Cks1 and Cks2 bind to Cdk1 at a high affinity and function as a suppressor of Cdk1 mutants.1, 3, 34 Despite the high sequence homology between the 2 members, whether Cks1 and Cks2 in mammalian cells elicit redundant or synergistic activities is not well understood although 1 report demonstrates that Cks1 compensates for Cks2 loss of function in the germ line.7 In mammalian cells, Cks1 induces an allosteric change in Skp2, which increases its affinity for phosphorylated p27kip1 and triggers ubiquitination of p27kip1, resulting in a rapid proteasome-mediated degradation of p27kip1 during G1/S transition in the cell cycle. To date, decreases in p27kip1 expression or mutations of p27kip1 has been reported in tumors of many tissue origins, including prostate cancer.35, 36 Here we showed that forced expression of Cks1 reduced p27kip1 in the cells and accelerated cell growth, while knockdown Cks1 expression in malignant AT3 cells inhibited proliferation and increased p27kip1 abundance (Fig. 2).
In addition to being a mitotic inhibitor, p27kip1 also has cell cycle-independent function, including regulating cell migration. However, p27kip1 has been shown both promoting and inhibiting cell migration.37–42 Recently, it has been showed that the binding of p27kip1 to the microtubule-destabilizing protein stathmin regulates the activity of p27kip1 to repress cell migration. Upregulation of p27kip1 or downregulation of stathmin expression results in inhibition of cell motility that is essential for invasion and metastasis of tumors.43, 44 Our data showed that knockdown of Cks1 expression increased p27kip1 abundance in the cells and inhibited cell migration, which was consistent with the finding that p27kip1 inhibits migration and invasion of tumor cells. In addition, inhibition of p27kip1 in LNCaP cells significantly increases colony formation in soft agar, suggesting that p27kip1 inhibits anchorage-independent growth activity of prostate cancer cells.45 Consistently, our data showed that knockdown of Cks1 expression increased abundance of p27kip1 and inhibited colony formation activity of the malignant AT3 cells. The result further suggests that overexpression of Cks1 might contribute to the tumorigenicity through promoting anchorage-independent growth activity.
In contrast to Cks1, knockdown of Cks2 expression in AT3 cells did not increase p27kip1 abundance. Instead, it slightly reduced the abundance of p27kip1. It is possible that the reduction of p27kip1 abundance in AT3 cells was a result of cell death caused by knockdown of Cks2 expression (Fig. 2). Further experiments are needed to address the issue. Similarly, forced expression of Cks2 did not reduce p27kip1albeit it accelerated DTE cell growth (Fig. 2). Therefore, although changes in Cks2 expression affect cell growth and has been shown to oscillate during the cell cycle,6 it is likely that Cks2 may not directly control the cell cycle progression. Indeed, expression of Cks2 in DU145, AT3 and TRAMP C2 cells was not reduced when the cells were cultured in serum-free medium for 48 hr (Supplemental Fig. 1), in which condition, the cell proliferation was relatively lower than in full culture medium. It is possible that changes in Cks2 expression may impact cell growth by preventing apoptosis. Both cell growth and apoptosis assays showed that knockdown of Cks2 expression in malignant AT3 cells had a more potent impact in cells maintained in nonoptimal culture conditions than in those maintained in optimal condition. This may explain why the leaky expression of Cks2 shRNA had limited effects on stock cell cultures that were maintained in the optimal conditions, yet, had significant effects on in vivo tumorigenesis analyses where the cells were implanted subcutaneously and did not have optimal supplies of oxygen and nutrition.
Together with the fact that Cks2 null mice did not have apparent defect in all tissues except the testes,7 our data here imply that Cks2 may not be essential for growth, differentiation and maintenance of normal prostatic cells, yet, is essential for protecting the cells from undergoing apoptosis in harsh growth conditions, such as deficient in nutritional or oxygen supplies. Thus, inhibition of Cks2 activity may be of therapeutic potential for tumor treatment, and promotion of Cks2 activity may be useful for preventing cells to undergo apoptosis because of insufficient oxygen or nutrition supplies, such as in stroke, heart attacks or other injury. In addition, although having distinct roles, the 2 Cks members may synergistically contributed to prostate tumorigenesis by promoting cell proliferation and preventing apoptosis.
In summary, here we report that aberrant expression of Cks1 in prostate tumor cells promoted tumorigenicity by promoting proliferation, anchorage-independent growth and cellular migration activity, while aberrant expression of Cks2 may promote the tumorigenicity by protecting the cells from apoptosis. Together with the reports that Cks1 and Cks2 are not essential for somatic cell growth and tissue homeostasis, the results here suggest a novel strategy for prostatic cancer treatment without affecting normal somatic cells.
The authors thank Dr. Wallace L. McKeehan, and Ms. Mary Cole for critical reading of the manuscript; Ms. Kerstin McKeehan for excellent technical supports.